Adalimumab in severe and acute sciatica: A multicenter, randomized, double‐blind, placebo‐controlled trial
Stéphane Genevay(University of Geneva), Cem Gabay(Hôpital Beau-Séjour), Federico Balagué, Axel Finckh(University Hospital of Geneva), Pascal Zufferey, Sébastien Viatte(National Health Service)
Cited by 63
Related Papers
What low back pain is and why we need to pay attention
|The Lancet|2018|4.7k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
Prevention and treatment of low back pain: evidence, challenges, and promising directions
|The Lancet|2018|2.5k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k